GleamWall
中文EN

ALMR Alamar Biosciences, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 2104204 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets19.7%
Debt / equity0.00x
Current ratio9.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$33.55M$29.43M$26.04M$19.91M$16.16M$13.09M
Cost of revenue$12.90M$11.71M$11.58M$8.02M$7.58M$6.70M
Gross profit$20.64M$17.72M$14.46M$11.90M$8.58M$6.39M
R&D expense$16.17M$13.82M$13.02M$10.21M$8.89M$8.30M
SG&A expense$19.62M$17.43M$13.79M$9.58M$7.61M$6.64M
Operating income-$15.14M-$13.53M-$12.35M-$7.88M-$7.92M-$8.55M
Pretax income-$13.25M-$13.29M-$20.86M-$7.56M-$7.02M-$7.66M
Income tax$94,000-$93,000$464,000$440,000——
Net income-$13.34M-$13.20M-$21.32M-$8.00M-$7.02M-$7.66M
EBITDA-$13.71M-$12.40M-$11.18M-$6.90M-$7.00M-$7.67M
EPS (basic)-0.19-0.22-1.74-0.69-0.62-0.68
EPS (diluted)-0.19-0.22-1.74-0.69-0.62-0.68
Weighted avg. shares (diluted)69.11M58.67M12.26M11.60M11.41M11.26M
Balance sheet
Cash & equivalents$121.53M$132.97M$64.59M$47.64M——
Short-term investments$105.05M$117.08M$0———
Receivables$21.61M$20.34M$19.52M———
Inventory$54.13M$45.41M$39.93M———
Current assets$317.69M$331.38M$141.47M———
PP&E, net$15.24M$13.36M$10.47M———
Total assets$378.03M$390.98M$186.45M———
Current liabilities$33.48M$27.96M$24.05M———
Total liabilities$74.32M$78.12M$129.53M———
Shareholders' equity$303.70M$312.86M-$178.07M-$153.34M-$146.61M-$140.29M
Cash flow statement
Operating cash flow-$14.73M-$11.32M-$20.35M-$14.14M-$11.88M-$13.07M
Capital expenditure$463,000$3.64M$600,000$1.22M$753,000$554,000
Free cash flow-$15.20M-$14.96M-$20.95M-$15.36M-$12.63M-$13.62M
Investing cash flow$11.74M-$120.80M-$778,000$14.19M$17.95M$17.02M
Financing cash flow-$9.85M$201.84M$55.76M$10.40M$164,000$243,000
Depreciation & amortization$1.42M$1.13M$1.17M$983,000$919,000$888,000
Stock-based compensation$3.92M$3.28M$1.47M$705,000$680,000$619,000

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.